Loading stock data…
Boundless Bio (BOLD)
$2.45-0.11 (-4.30%)
Market ClosedLast close Jun 29
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Boundless Bio, Inc. in the Healthcare sector is trading at $2.45 with a market capitalization of $32M. Wall Street consensus targets $4.00 (1 analysts), implying a +63.3% move over the next 12 months. The stock is currently near its 52-week high of $2.79, remaining 88.5% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +63.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.47M↓ | -$14.00M↑ | -$15.15M↑ | -$17.06M↑ | -$17.34M |
| Net Income | -$13.55M↓ | -$12.88M↑ | -$13.88M↑ | -$15.68M↑ | -$15.76M |
Peer Comparison
JNJUNHPFE
Fundamentals
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.90M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.82%
Volume
Today's trading volume
285,818
Recent News
Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today
Investors showed interest in businesses tied to artificial intelligence infrastructure, advanced biotechnology, and quantum computing.
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State S
BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History
Boundless Bio is set to merge with Serapha Bio, with the transaction set to close in the fourth quarter of 2026.
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.